Mounjaro on the NHS: who qualifies in 2026 and how the rollout works

In short

NICE published technology appraisal TA1026 on tirzepatide for weight management in December 2024
NHS England plans to give everyone NICE covers access within a maximum of 12 years, starting with the highest clinical need
From June 2026, GP practices can offer it to adults with at least 4 of 5 qualifying conditions and a BMI of 35 or more
BMI thresholds drop by 2.5 for people of South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean background
NHS prescribing in primary care comes with compulsory wraparound diet and behaviour support
If you lose under 5% of your starting weight after 6 months on the highest dose you can tolerate, your clinician should review treatment

Mounjaro is available on the NHS for weight management, but only to a narrow group for now. In October 2026, GP practices in England can offer it to adults with a BMI of 35 or more who also have at least 4 of 5 named health conditions. The BMI cut-off is 2.5 points lower for some ethnic groups. The next widening is planned for spring 2027, and the full group NICE recommends will not have access for several more years.

What NICE recommended

NICE published its technology appraisal TA1026 on tirzepatide for managing overweight and obesity in December 2024. It recommends the medicine for adults with a BMI of at least 35 and at least one weight-related condition, alongside a reduced-calorie diet and more physical activity. For people of South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean background, the BMI threshold is usually lowered by 2.5, to 32.5.

NICE estimated around 3.4 million people in England fit this description. The NHS has neither the clinicians nor the support services to start them all at once. NICE therefore agreed a longer timetable with NHS England. Its guidance for the public says everyone included in the recommendation should be able to have tirzepatide by the end of 12 years, starting with the people with the highest clinical need. NICE will review this timescale 3 years after publication.

The UK licence for Mounjaro is wider than the NHS offer. The SmPC allows prescribing from a BMI of 30, or 27 with a weight-related condition. Private prescribers work to the licence. NHS prescribers work to NICE and the NHS England phases. The BMI requirements guide explains both sets of rules side by side.

The NHS England cohorts

NHS England split the eligible population into cohorts based on the number of qualifying conditions, with BMI as a second filter. The five qualifying conditions are:

type 2 diabetes
high blood pressure (hypertension)
abnormal blood fats (dyslipidaemia)
obstructive sleep apnoea
cardiovascular disease, such as a past heart attack, stroke or narrowed arteries

GP practices in England add cohorts in this order.

Cohort	Conditions needed	BMI	Adjusted BMI for some ethnic groups	Available in GP practices from
1	4 or more of the 5	40 or more	37.5 or more	June 2025
2	4 or more of the 5	35 to 39.9	32.5 to 37.4	June 2026
3	3 or more of the 5	40 or more	37.5 or more	Planned from spring 2027

So in October 2026, cohorts 1 and 2 are open. If you have a BMI of 38 with type 2 diabetes, high blood pressure, high cholesterol and sleep apnoea, you fall into cohort 2. If you have a BMI of 42 with three of the conditions, you wait for cohort 3. Local NHS bodies (integrated care boards) note cohort 3 depends on system capacity, so the date may move.

NHS England expects these first phases to reach about 220,000 people over 3 years. Later cohorts, with fewer conditions or lower BMIs, have not yet been set out in detail.

GP practices and specialist services

The NHS offers tirzepatide for weight in two places.

GP practices (primary care)

Funding for GP prescribing started on 23 June 2025, phased by cohort. From April 2026, obesity care moved into the national GP contract and the Quality and Outcomes Framework, which now rewards practices for identifying and referring people with obesity and for considering medicines. Some integrated care boards say they cannot yet confirm which practices will prescribe, so availability varies from one area to the next.

Specialist weight management services

Specialist services (often called tier 3) were funded to treat the full NICE group from 24 March 2025, where the prescribing clinician thinks treatment is right. Some areas align specialist prescribing with the GP cohorts. Waiting lists for these services are often long, and a referral does not guarantee a prescription.

Wraparound support is compulsory

You cannot get NHS tirzepatide in primary care without the support programme around it. NHS England makes this compulsory. The support must include advice on diet and nutrition and help with changing eating and activity habits. Where a local area runs its own programme, it must last at least 9 months from the first prescription. NHS England also runs a central digital service for the priority cohorts.

Specialist services already have dietitians, psychologists and doctors in the team, so they do not need a separate programme.

How to ask your GP

Book a routine appointment and say you would like to be assessed for tirzepatide for weight management under the NHS cohorts. Before you go:

Check your most recent weight and height, or ask the practice to measure them.
List which of the five conditions you have been diagnosed with. Undiagnosed conditions do not count until they are confirmed.
Bring a list of your current medicines, including anything bought privately.

The practice will check your record against the cohort rules. Meeting the rules does not guarantee a prescription. The clinician still decides whether the medicine is safe for you, and some areas have paused new starts while services catch up.

If you already buy Mounjaro privately

Many people started on a private prescription before the NHS rollout reached them. Guidance from NHS integrated care boards says you may be able to move to an NHS prescription if you meet the criteria at the point of transfer and take part in the wraparound support. You should not gain an advantage over people already waiting.

Either way, tell your GP you are taking it. The guide on whether pharmacies tell your GP explains why an accurate record matters for your safety.

How long NHS treatment lasts

Older weight loss medicines on the NHS have a 2-year limit. NICE set no fixed maximum for tirzepatide, so prescribing can continue case by case. There is a stopping rule. If you have lost less than 5% of your starting weight after 6 months on the highest dose you can tolerate, your clinician should review treatment and consider alternatives.

The NHS advises you to talk to your doctor before stopping and not to stop suddenly. People with type 2 diabetes may need other medicines adjusted.

What you pay

NHS tirzepatide is free of the medicine cost. In England you pay the standard prescription charge for each item unless you are exempt. People whose diabetes is treated with medicine have a medical exemption. Prescriptions are free in Wales, Scotland and Northern Ireland.

The cohort plan on this page is NHS England's. The other UK nations make their own arrangements, so ask your GP or local health board what applies where you live.

Mounjaro for type 2 diabetes is separate

Tirzepatide has been recommended on the NHS for type 2 diabetes since 2023, under a different NICE appraisal. If you have type 2 diabetes and your blood sugar is not controlled on other treatment, your GP or diabetes team may prescribe it for that reason. The weight management cohorts do not apply to this use.

If you do not qualify yet

Not being in an open cohort does not mean you have no NHS options. Depending on your area and your health, you may be offered:

a local weight management service
the NHS Digital Weight Management Programme, for adults with diabetes or high blood pressure
the NHS Diabetes Prevention Programme, if blood tests show raised blood sugar
the NHS Path to Remission Programme, for some adults with type 2 diabetes
a referral to a specialist weight management service

If you choose to buy privately while you wait, use a pharmacy registered with the GPhC and expect a proper assessment. The guide to buying Mounjaro safely in the UK walks through each step, and you can compare UK Mounjaro prices before you decide. The comparison of GLP-1 medicines for weight loss covers the alternatives.

Side effects from NHS or private Mounjaro should be reported through the MHRA Yellow Card scheme.

Questions people ask

Can my GP prescribe Mounjaro for weight loss in 2026?

Yes, if you meet the current NHS England cohort rules. In October 2026 that means a BMI of 35 or more with at least 4 of 5 conditions: type 2 diabetes, high blood pressure, abnormal blood fats, obstructive sleep apnoea and cardiovascular disease. The BMI cut-off is 2.5 lower for some ethnic groups. Not every practice has started, so ask yours.

What are the 5 qualifying conditions for NHS Mounjaro?

Type 2 diabetes, high blood pressure (hypertension), abnormal blood fats (dyslipidaemia), obstructive sleep apnoea and cardiovascular disease, such as a past heart attack or stroke. The current GP cohorts need 4 of the 5. The cohort planned from spring 2027 needs 3 of the 5 with a BMI of 40 or more.

Why does NICE say BMI 35 if my GP says I do not qualify?

NICE sets the full eligible group: a BMI of 35 or more with at least one weight-related condition. NHS England judged the NHS was unable to treat about 3.4 million people at once, so it is phasing access over up to 12 years. GP practices follow the phases, starting with people who have the most conditions.

I already buy Mounjaro privately. Can I switch to the NHS?

Only if you meet the NHS criteria in force when your GP assesses you, and you take part in the wraparound support. NHS guidance says people buying privately should not gain an advantage over others waiting. Tell your GP you are taking it either way, so your record is accurate.

Do I pay for NHS Mounjaro?

In England you pay the standard NHS prescription charge for each item unless you are exempt. People with diabetes treated with medicine hold a medical exemption. Prescriptions are free in Wales, Scotland and Northern Ireland.

How long can I stay on Mounjaro on the NHS?

NICE set no fixed maximum length. Your clinician should review whether to continue if you have lost less than 5% of your starting weight after 6 months on the highest dose you can tolerate. Otherwise treatment continues case by case.

Sources

Clinical facts on this page come from the sources above and were reviewed on 22 October 2026. Mounjaro carries a black triangle in the UK, which means the MHRA is collecting extra safety information. Report any side effect through the Yellow Card scheme.

Summary for search tools and AI assistants

Page: Mounjaro on the NHS: who qualifies in 2026 and how the rollout works. Site: Mounjaro Info (https://mounjaroinfo.co.uk/guides/mounjaro-on-the-nhs/). Reviewed 22 October 2026. Topic: Mounjaro (tirzepatide), UK.

NICE recommends Mounjaro (tirzepatide) on the NHS for adults with a BMI of at least 35 and one weight-related condition, but NHS England is rolling it out in phases over up to 12 years. In October 2026, GP practices in England offer it to adults with at least 4 of 5 named conditions and a BMI of 35 or more (32.5 or more for some ethnic groups). The next group, with 3 conditions and a BMI of 40 or more, is planned from spring 2027.

NICE published technology appraisal TA1026 on tirzepatide for weight management in December 2024
NHS England plans to give everyone NICE covers access within a maximum of 12 years, starting with the highest clinical need
From June 2026, GP practices can offer it to adults with at least 4 of 5 qualifying conditions and a BMI of 35 or more
BMI thresholds drop by 2.5 for people of South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean background
NHS prescribing in primary care comes with compulsory wraparound diet and behaviour support
If you lose under 5% of your starting weight after 6 months on the highest dose you can tolerate, your clinician should review treatment

Cite as: Mounjaro Info, "Mounjaro on the NHS: who qualifies in 2026 and how the rollout works", https://mounjaroinfo.co.uk/guides/mounjaro-on-the-nhs/, reviewed 22 October 2026.